Palatin Technologies, Inc. (PTN) stock declined over -4.80%, trading at $9.52 on NASDAQ, down from the previous close of $10.00. The stock opened at $9.88, fluctuating between $9.50 and $10.04 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 13, 2026 | 9.89 | 10.19 | 9.50 | 9.52 | 8.55K |
| Jul 10, 2026 | 10.29 | 10.29 | 9.77 | 10.00 | 14.55K |
| Jul 09, 2026 | 9.98 | 10.96 | 9.98 | 10.49 | 7.87K |
| Jul 08, 2026 | 10.55 | 10.68 | 10.22 | 10.27 | 17.77K |
| Jul 07, 2026 | 11.40 | 11.40 | 9.78 | 10.99 | 15.79K |
| Jul 06, 2026 | 11.51 | 11.60 | 10.73 | 11.01 | 12.07K |
| Jul 02, 2026 | 10.88 | 11.71 | 10.11 | 11.59 | 25.55K |
| Jul 01, 2026 | 11.22 | 11.22 | 9.75 | 10.33 | 147.05K |
| Jun 30, 2026 | 10.46 | 11.35 | 10.23 | 10.79 | 14.27K |
| Jun 29, 2026 | 11.01 | 11.01 | 10.05 | 10.34 | 36.7K |
| Jun 26, 2026 | 10.86 | 11.56 | 10.86 | 11.44 | 28.85K |
| Jun 25, 2026 | 10.90 | 10.90 | 10.25 | 10.25 | 11.58K |
| Jun 24, 2026 | 11.01 | 11.01 | 9.99 | 10.60 | 23.8K |
| Jun 23, 2026 | 11.30 | 12.18 | 11.00 | 11.21 | 16.25K |
| Jun 22, 2026 | 11.31 | 11.95 | 11.31 | 11.77 | 23.42K |
| Jun 18, 2026 | 11.91 | 12.21 | 11.72 | 11.72 | 11K |
| Jun 17, 2026 | 12.25 | 12.25 | 12.24 | 12.25 | 3.07K |
| Jun 16, 2026 | 12.51 | 12.51 | 11.31 | 11.87 | 15.97K |
| Jun 15, 2026 | 14.01 | 14.01 | 12.05 | 12.50 | 21.7K |
| Jun 12, 2026 | 13.70 | 14.41 | 13.00 | 13.60 | 6.86K |
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
| Employees | 29 |
| Beta | -0.11 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | June |
| Sector | Healthcare |
| Industry | Biotechnology |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep